Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Shares Traded Last Trade
  16.00 3.96% 420.50 25,846 12:49:38
Bid Price Offer Price High Price Low Price Open Price
417.00 425.00 425.00 420.00 421.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 166.75 -138.78 -13.17 3,131
Last Trade Time Trade Type Trade Size Trade Price Currency
12:43:24 O 4,000 416.93 GBX

Hutchison China Meditech (HCM) Latest News

More Hutchison China Meditech News
Hutchison China Meditech Investors    Hutchison China Meditech Takeover Rumours

Hutchison China Meditech (HCM) Discussions and Chat

Hutchison China Meditech Forums and Chat

Date Time Title Posts
14/4/202113:55(Chi-Med)Hutchinson China Meditech Limited3,110
31/7/201807:25Hutchison Chi-Med (HCM) One to Watch 1
23/7/201810:55Hutchison Chi-Med (HCM) One to Watch on Monday 1
13/6/201707:54Hutchison China Meditech- CHARTS AND DISCUSSION74

Add a New Thread

Hutchison China Meditech (HCM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Hutchison China Meditech trades in real-time

Hutchison China Meditech (HCM) Top Chat Posts

Hutchison China Meditech Daily Update: Hutchison China Meditech Limited is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchison China Meditech was 404.50p.
Hutchison China Meditech Limited has a 4 week average price of 384p and a 12 week average price of 384p.
The 1 year high share price is 538p while the 1 year low share price is currently 282p.
There are currently 744,515,660 shares in issue and the average daily traded volume is 28,014 shares. The market capitalisation of Hutchison China Meditech Limited is £3,126,965,772.
steeplejack: I'm becoming increasingly sceptical if there's anything imminent thats going to trigger some damascene experience in the share price fortunes of HCM.There are some very old brooms managing this company,brooms that were employed by Hutchinson Whampoa many years ago.As capable as these old hands maybe,i reflect that fresh management might be more conscious that this is now an independent company,no longer a consolidated subsidiary.The relative underperformance of the NASDAQ over the last three years should be a real cause for concern for a company that's tapping investors from time to time.The investment message simply isn't getting across and that is costing HCM money re dilution.
lauders: Also, being ever the contrarian, the lack of seeing you sign off with "I continue to buy" recently was a factor as well :) LOL Bareknee. Surely unintentional, but you could be right that it is a "sign". HCM are definitely out of favour at present. No doubt patience will be rewarded if bought at these levels. If I had excess cash floating around looking for a home some would almost certainly find its way here. Alas I just have to hold what I have now for the time being. Being patient when the share prices of other companies around seem to reach new highs daily at present is tough though!
sportii: Not sure the company gives any importance to investors’ interests. Its glaringly true that the market valuation is very very low. Is there another pharma company of this magnitude with such low market valuation? Over the last 5/6 years, on 4-5 occasions, the share price climbed up on a steady pace, backed up by genuinely solid reasons(successful clinical trials, extending operational activities to the USA, enviable pipeline, triple hundred millions of investments by two major funds, drugs getting approved by authorities and subsequent marketing etc., etc.). However, on every occasion, share price failed to maintain the higher valuation longer than few weeks due to various (some times without any) reasons. For example, 6-8 weeks ago, AIM share price was > £5.30 and NYSE ADRs > $37. One fine day, following the announcement of reasonably satisfactory annual results, more than a million ADRs got traded (?sold) which caused severe drop in the share price Surprisingly, the very following day, a million ADRs got (?)bought, with no improvement in the sp! Presently, share price is languishing at £4 (and ADRs $27). The company keeps the news of Asian listing in the circulation as a hope for the investors. Is it a carrot hanging at a distance? Personally, I feel appreciating Hutchmed for the great work of research and development of newer therapies for oncology and immunology which, undoubtedly, will be useful to millions of people. But, as an investor I remain seriously sceptical about poor show in improving market valuation. (PS: no intention of recommending either to buy or sell. Do your own research)
sportii: The company had number of ‘breakthrough’ opportunities viz, approval for fruquintinib/ and launching of Elunate/Sulanda. What exactly is the intention behind the precondition of ‘commercialisation success’ for listing at HK/ STAR? There weren’t any such preconditions before listing at London and NYSE. Is the management ‘concernedR17; with a much higher share price? Or, is a lower share price much preferred for some unknown reason?
dbadvn: Follow up on call with CH. Tried to cover all your questions , but may have missed a few , anyway in no particular order. 1. Asian listing/ share price/cash flow Share price was probably ahead of the market at end of 2017 . This was followed by 2018 setback of AZN cancelling the Savvanah ( ?) ph3 study .( which turned out to actually be wrong ). 2019 clumsy consolidation by Huchison ( learned lesson , will not sell into market again , only to large 3rd party if at all ). Very recent falls just part of Asian Biotech sell off in general . Even CH feels capitalisation should be around 8-10bn, pipeline not being correctly valued / recognised. Asian listing very much at forefront and cannot say more, But later on had conversation on lining up large investors implying that listing will be within next 9 months. Conditions are aligning. Cash in next 2years will come from large investors , sale of OCI business, improved profits as new drugs get to market . Did not rule out placing but not say would be needed either. Also made the point that large investors ( Fidelity etc) were very pleased with results and progress . Selling down has been by early investors who have lightened their positions and mainly by Far East groups ( Mitsui). 2. AZN Relationship / JUnshi deal etc Had to really hold Azn feet to the fire but they are now responding ( Eli Lilly much worse , very relieved to be out of that deal ) especially in China. Assuming Savo approval By Q3 they will have 2000 reps selling ( what? - did not understand this ) . Should bring in $250m at 30% royalty in 2022. Azn/ Junshi not of particular concern , not really competition as different drug market . Tagrisso/Savo combo outside of China now moving ahead at good pace. 3. Inmagene deal. Need to concentrate of Oncology development Immunology is a very different market . Requires a completely different team and a long term approach ( long term ongoing treatment so drugs must have low / no toxicity , large placebo effect ) Inmagene only have options up to Ind stage so not given too much away but saved the expenditure and the distraction . Not v clear on savings but probably North of $200m) depending on success of asset. Inmagene execs are ex HCM but almost every Biotech in China has ex HCM execs as they have been around so long. Team is very well connected to industry bodies in China , 4 Patient access programme in US/Can ? Not possible without full approval. In China non approved drugs can be used at Doctor's discretion , "off label", but not allowed to actively market a drug before approval ( hence large conferences = pseudo marketing) 5. Seroquel - no mention sorry. 6. Leveraging sales by doing deals with Multinationals. Being approached all the time to sell on behalf of Multinatiuonal in China , and sell licence to Multinational outside China. Open minded , if the deal is right then may do it but so far experience with Eli Lilly and Azn has not really encouraged them in this direction. Knows Beigene CEO very well ( partnered with Surafatinib). This was a fantastic deal for Beigene especially as they were behind in the market compared to Merck/ Pfizer/ Roche. Still it was a one time plug , gave away huge forward revenue stream . 7 Future. Getting more and more excited by 689 , extraordinary results ( also large market). 523 and 306 also coming along better than expected . 453 - back burner due to toxicity. 8 Overall - CH recognises investor frustration but insists that barring extraordinary events next 12 months should be a "very exciting time " for investors. Thats it. D
whatja: The press releases always focus on the facts that are agreed by both sides. they leave out the reason for the deal as that might expose weaknesses on both sides. Imagine writing it up as: INmagine has agreed to fund the development of four discoveries that HCM can’t be bothered with and has guaranteed a large profit for HCM on each successful candidate....The chances of success are low for any particular candidate, may still be low for one of four to proceed to approval. Or HCM has a prolific discovery engine but has not invested in its clinical capability and cannot afford to progress all its promising early stage. Significant value has been transferred to a developer in return for no upfront payment and a small unspecified royalty. Not flattering for either side so we get a strategic partnership to develop a portfolio of new candidates. HCM has identified a number of promising drug candidates and its partner is experienced in developing such products implies more likely to be successful. Terms give HCM milestone payments and royalties so generating a future profit stream. Everyone is happy! We need to read between the lines and interpret CHs comments to see what we think drives the deal and therefore whether it is a net gain or loss. I suspect that it does create value from early stage candidates and eases cash flow demands in 22/23/24.
steeplejack: Hutchison China MediTech (HCM)Last but not least is a $4 billion holding company in China's drug manufacturing sector. Hutchison China MediTech, doing business as Chi-Med, owns a group of subsidiaries engaged in the manufacture and distribution of pharmaceuticals. HCM's products include over the counter medications and consumer healthcare items, as well as sophisticated therapeutics and immunotherapies for the treatment of cancer and autoimmune disorders.As with many pharmaceutical companies, HCM's share price is driven by the company's approved products and development pipeline. In this area, HCM has two advantages.First advantage is Elunate, a drug approved by Chinese regulators as a treatment for colorectal cancer. The company has been working with Eli Lilly, one of the giants of Big Pharma, to fast-track marketing and patient access; earlier this year, that agreement was amended to improve commercialization efforts on Elunate to include all of China.The second advantage is Savolitinib, a drug developed as a treatment for some types of non-small cell lung cancer. The company's New Drug Application (NDA), a key milestone in regulatory approval, has been accepted by China's National Medical Products Administration.Both drugs are being investigated for additional indications, and are part of an active pipeline at the company, which includes nine medications in various stages of development.Among the fans is Deutsche Bank analyst Rajan Sharma who rates HCM a Buy. His $40 price target shows the extent of his confidence, implying ~37% upside for the coming year. (To watch Sharma's track record, click here)Defending his bullish stance on HCM, Sharma writes, "We believe Chi-Med is well on track in its evolution from a Chinese pharmaceutical/OTC company into a fully integrated, innovative global oncology company [...] We see the next steps of Chi-Med's evolution as being approval of its first solely developed drug and launches outside of China, particularly in the US. The company is on track to achieve both of these in the next two years."All in all, HCM has earned a Moderate Buy consensus rating, with 2 Buy reviews in the past three months. Shares are priced at $29.28 and the $40 average price target matches Sharma's. (See HCM stock analysis on TipRanks)
nerdofsteel: indeed miti, let's hope so. I have a very large position here as you know, and I've been extremely disappointed in the share price over the last 4 years - I could have made a lot of money investing in my other favorites - Beigene, Genmab and Juno so my loyalty to the company has cost me dearly. I hope 2021 will reverse that. I always get perplexed when I look at Beigene, how it grew so quickly by striking deals with other big pharma etc We seem to be very (too) conservative and lack innovation on the corporate side. For example, given our distribution and sales channels in China, why haven't we leveraged that to in-licence and resell blockbusters like Beigene did with Celgene? That would have allowed us to ramp up the sales channel and get significant financial uplifts whilst still developing our own pipeline. Chi-Med seem to have the view they want to focus on their own innovation but why not have parallel growth strategies. If the share price is still in the 400's by the end of 2021 I will have to invest elsewhere. I hope that is not the case.
miti 1000: Having sold out at the highs of 550 a few years back when MSCI china funds had to buy the stock, I thought I'd revisit hcm. Long term posters(Matt) moan about moving the listing (FFS, its already on 2 indices!!Get a grip, man) and others simply just chose to ignore Savo/Tagrisso and the lack of an interim readout. Despite the huge bullishness on here , lets be honest, Savolitinib which is what controls the share price has just not progressed as the company wished( remember it failed in one indication 3 years ago) but luckily , the share price rose cos of the aforementioned fund buying allowing me a great exit. There has been been no interim readout of data in combination with Tagrisso.In fact, it has now been called an 'Internal' readout so clearly there appears to be issues in the poster child killer application and indicates things are not progressing to plan . I presume they will have to come out with proper details in 2021 and either the share price will halve or it will go thru the roof if it works after tweaks. This explains why the share price ash gone nowhere but lower since I sold despite such huge gains elsewhere in the sector. I made a huge gain last time on HCM but I'm just not tempted this time even after a 30% fall since I sold almost 3 years. Hard to invest in big size on such a binary bet when the signs don't seem promising on savo/tagrisso.
dbadvn: HCM share price , lacking the ridiculous hype surrounding other biotechs, and any takeover premium , will follow the numbers. It will start to rocket as soon as the market sees the cash being thrown off in the next few years as sales rise rapidly.
Hutchison China Meditech share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Hutchison ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210415 12:10:51